In an article from Forbes, Matthew Herper questions whether a move by Roche to buy out Genentech will be a good or bad thing. Roche already owns a majority stake in the biotech company, but recently made what analysts have called a lowball bid of $43.7 billion to acquire the rest. Genentech might stand to gain from going invisible, but for the most part, its unique culture is what's most worth saving, Herper says. "The most important part of Genentech's value is in soft assets -- the world-leading scientists, the culture, the single site, the values and history," says analyst Geoffrey Porges.